Subject(s)
Cyclosporins/metabolism , Heart Transplantation , Liver Transplantation , Adolescent , Adult , Biopterins/analogs & derivatives , Biopterins/blood , Child , Chromatography, High Pressure Liquid , Cyclosporins/administration & dosage , Cyclosporins/pharmacology , Dose-Response Relationship, Drug , Humans , Lymphocyte Activation/drug effects , Middle Aged , Neopterin , RadioimmunoassayABSTRACT
The PTH secretion was studied in fragments of 83 (reactive) hyperplastic parathyroids (type 1 a: n = 24; type 1 b: n = 20, type 2: n = 39) simulating hypo- (0.3 mmol Ca++ = maximal PTH secretion), normo- (0.9 and 1.2 mmol Ca++) and hypercalcemia (3.0 mmol Ca++ = basic PTH secretion, maximal suppressibility) in vitro. 56 out of 83 glands (67%) were suppressible (PTH secretion decreased under 50% of maximal secretion) with no significant difference in suppressibility of diffuse and nodular hyperplasia (50% and 74%, respectively). Differentiating diffuse hyperplastic glands in those with (type 1 a) and without (type 1 b) stroma fat cells, 92% of type 1 a glands and only 25% of type 1 b glands were suppressible (Fischer's test: p less than 0.001). Separated (oxyphilic and/or chief cell) nodules, type 1 b- and type 1 a-like areas (both localized between nodules) of types 2 glands were suppressible in 18%, 17% and 91%, respectively (Fischer's test: p less than 0.001). Thus fragments of type 1 a regions should be autotransplanted for preference. Type 1 b regions or nodules should not be used for grafting.
Subject(s)
Hyperparathyroidism, Secondary/surgery , Kidney Failure, Chronic/complications , Parathyroid Glands/transplantation , Parathyroid Hormone/metabolism , Calcium/blood , Graft Survival , Humans , Hyperparathyroidism, Secondary/physiopathology , Mitotic Index , Parathyroid Glands/physiopathology , Parathyroid Glands/surgery , PrognosisABSTRACT
Osteocalcin is a non-collagenous bone matrix protein which is released into the circulation and can be measured by radioimmunoassay. Recent studies indicate that serum osteocalcin concentrations are a marker of bone formation. Because bone demineralisation is a common finding in patients with rheumatoid arthritis (RA) the serum osteocalcin concentrations and, in addition, the serum concentrations of 25-hydroxyvitamin D, parathyroid hormone, and calcitonin were measured in 29 patients with RA and in 30 control subjects. Whereas serum osteocalcin concentrations were similar in patients with RA and in control subjects, serum 25-hydroxyvitamin D concentrations were significantly decreased in patients with RA. Serum concentrations of parathyroid hormone and calcitonin in patients with RA and in control subjects were not statistically different. The normal osteocalcin concentrations in patients with RA suggest a normal rate of bone formation in these patients.